Drug recall · July 17, 2019
Losartan Potassium and Hydrochlorothiazide Tablets recall
Why: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Losartan Potassium and Hydrochlorothiazide Tablets, USP 100 mg/12.5 mg 90 Tablets, USP Manufactured for: Macleods Pharma USA inc. Plainsboro, NJ 08536 Manufactured by: Macleods Pharmaceuticals, Ltd. Baddi, Himachal Pradesh, INDIA NDC 33342-051-10
- Lots / codes
BLL801A Dec-19 BLL802A Dec-19 BLL803A Dec-19
- Quantity
- 29106 bottles (2,619,540 tablets)
- Company
- Macleods Pharma Usa Inc, Plainsboro, NJ
- Distribution
- Nationwide
- Initiated
- June 20, 2019 · Voluntary: Firm initiated
- Classified
- July 9, 2019
- Reported
- July 17, 2019
- Ended
- October 26, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hydrochlorothiazide / losartan
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.